Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-24T05:02:19.765Z Has data issue: false hasContentIssue false
  • English
  • Français

Salivary duct carcinoma: what is already known, and can we improve survival?

Published online by Cambridge University Press:  12 April 2012

D T H Wee ,
A A Thomas  and
P J Bradley
D T H Wee*
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
A A Thomas
Affiliation:
Department of Anatomical Pathology, PathWest Laboratory Medicine, Queen Elizabeth II Medical Centre, Perth, Western Australia, Australia
P J Bradley
Affiliation:
Department of Head and Neck Surgery, Nottingham University Hospitals, Queen's Medical Centre Campus, Nottingham, UK
*
Address for correspondence: Dr Desmond Tiong Hien Wee, Department of Otorhinolaryngology – Head and Neck Surgery, Sir Charles Gairdner Hospital, Hospital Ave, Nedlands, Western Australia, Australia6009 E-mail: desmondwee@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Salivary duct carcinoma is an aggressive malignancy with a high mortality rate, which phenotypically resembles high-grade breast ductal carcinoma. The parotid gland is the most common location. Standard treatment is surgery to the primary tumour together with post-operative radiotherapy. Despite this, there is a high rate of local recurrence, cervical nodal involvement and distant metastasis. Chemotherapy is currently considered only for end-stage, disseminated disease; however, current evidence indicates that chemotherapy used with radiotherapy may result in improved disease control and survival.

Human epidermal growth factor receptor-2 is a proto-oncogene which is over-expressed in both breast ductal carcinoma and salivary duct carcinoma. Clinical studies of patients with metastatic breast cancer, using trastuzumab, a monoclonal antibody directed against human epidermal growth factor receptor-2, have shown significant efficacy in tumour response, resulting in improved survival. Such advances in immunohistochemistry, and in targeted immunotherapy for breast ductal carcinoma, should be applied to the treatment of salivary duct carcinoma.

Keywords

Salivary Duct CarcinomaMalignant Salivary NeoplasmsParotid GlandSalivary Gland Cancer
Type
Review Article
Information
The Journal of Laryngology & Otology , Volume 126 , Supplement S2 , July 2012 , pp. S2 - S7
Copyright
Copyright © JLO (1984) Limited 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Kleinsasser, O, Klein, HJ, Hubner, G. Salivary duct carcinoma: a group of salivary gland tumours analogous to mammary duct carcinoma [In German]. Arch Klin Exp Ohren Nasen 1968;192:100–5CrossRefGoogle ScholarPubMed
2Ellis, GL, Auclair, PL, Gnepp, DR, Goode, RK, eds. Surgical Pathology of the Salivary Glands. Philadelphia: Saunders, 1991Google Scholar
3Seifert, G, Batsakis, JG, Brocheriou, C. World Health Organization International Classification of Tumours: Histological Typing of Salivary Gland Tumours, 2nd edn.Berlin: Springer-Verlag, 1991CrossRefGoogle Scholar
4Gnepp, DR, Henley, JD, Simpson, RHW, Eveson, J. Salivary and lacrimal glands. In: Gnepp, DR, ed. Diagnostic Surgical Pathology of the Head and Neck, 2nd edn.Philadelphia: Saunders Elsevier, 2009Google Scholar
5Barnes, L, Rao, U, Krause, J, Contis, L, Schwartz, A, Scalaogna, P. Salivary duct carcinoma. Part I. A clinicopathological evaluation and DNA image analysis of 13 cases with a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1994;78:64–73CrossRefGoogle Scholar
6Jaehne, M, Roeser, L, Jaekel, T, Schepers, JD, Albert, N, Löning, T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005;103:2526–33CrossRefGoogle ScholarPubMed
7Delgado, R, Klimstra, D, Albores Saavedra, J. Low-grade salivary duct carcinoma. A distinctive variant with low-grade histology and a predominant intraductal growth pattern. Cancer 1996;78:958–673.0.CO;2-8>CrossRefGoogle Scholar
8Eveson, J, Watkinson, J. The WHO histological classification of salivary gland tumours: is it overelaborate for clinical use? In: McGurk, M, Renehan, A, eds. Controversies in the Management of Salivary Gland Disease. New York: Oxford University Press, 2001Google Scholar
9Barnes, L, Eveson, JW, Reichart, P, Sidransky, D, eds. World Health Organization Classification of Tumours, Pathology and Genetics, Head and Neck Tumours. Lyon: IARC Press, 2005;9Google Scholar
10Laco, J, Podhola, M, Dolezalova, H. Low-grade cribriform cystadenocarcinoma of the parotid gland: a neoplasm with favourable prognosis, distinct from salivary duct carcinoma. Int J Surg Path 2010;18:369–73CrossRefGoogle ScholarPubMed
11Brandwein-Gensler, M, Hille, J, Wang, BY, Urken, M, Gordon, R, Wang, LJ et al. Low-grade salivary duct carcinoma: description of 16 cases. Am J Surg Pathol 2004;28:1040–4CrossRefGoogle Scholar
12Brandwein-Gensler, MS, Skalova, A, Nagao, T. Salivary duct carcinoma. In: Barnes, L, Eveson, JW, Reichart, P, Sidransky, D, eds. World Health Organization Classification of Tumours, Pathology and Genetics, Head and Neck Tumours. Lyon: IARC Press, 2005;9Google Scholar
13Lewis, JE, McKinney, BC, Weiland, LH, Ferreiro, JA, Olsen, KD. Salivary duct carcinoma: clinicopathologic and immunochemical review of 26 cases. Cancer 1996;77:223–303.0.CO;2-N>CrossRefGoogle Scholar
14Simpson, RH, Di Palma, S. Selected recent advances in the pathology of salivary neoplasms. Diagn Histopathol (Oxf) 2010;16:276–82CrossRefGoogle Scholar
15Hosal, AS, Fan, C, Barnes, L, Myers, EN. Salivary duct carcinoma. Otolaryngol Head Neck Surg 2003;129:720–5CrossRefGoogle ScholarPubMed
16Lewis, JE, Olsen, KD, Sebo, TJ. Carcinoma ex-pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol 2001;32:596–604CrossRefGoogle ScholarPubMed
17Olsen, KD, Lewis, JE. Carcinoma ex-pleomorphic adenoma: a clinicopathologic review. Head Neck 2001;23:705–12CrossRefGoogle ScholarPubMed
18Zbaren, P, Zbaren, S, Caversaccio, MD, Stuffer, E. Carcinoma ex-pleomorphic adenoma: diagnostic difficulty and outcome. Otolaryngol Head Neck Surg 2008;138:601–6CrossRefGoogle ScholarPubMed
19Simpson, RHW, Desai, S, Di Palma, S. Salivary duct carcinoma in situ of the parotid gland. Histopathology 2008;53:416–25CrossRefGoogle ScholarPubMed
20Cheuk, W, Chan, JKC. Advances in salivary gland pathology. Histopathology 2007;51:1–20CrossRefGoogle ScholarPubMed
21McHugh, JB, Vissher, DW, Barnes, L. Update on selected salivary gland neoplasms. Arch Pathol Lab Med 2009;133:1763–74CrossRefGoogle ScholarPubMed
22Simpson, RH, Prasad, AR, Lewis, JE, Skalova, A, David, L. Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Path 2003;27:1070–9CrossRefGoogle ScholarPubMed
23Nagao, T, Gaffey, TA, Visscher, DW, Kay, PA, Minato, H, Serizawa, H et al. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance. Am J Surg Pathol 2004;28:319–26CrossRefGoogle ScholarPubMed
24Yamamoto, H, Uryu, H, Segawa, Y, Tsuneyoshi, M. Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland. Pathol Internat 2008;58:322–26CrossRefGoogle ScholarPubMed
25Delgado, R, Vuitch, F, Albores-Saavedra, J. Salivary duct carcinoma. Cancer 1993;72:1503–123.0.CO;2-K>CrossRefGoogle ScholarPubMed
26Padberg, BC, Sasse, B, Huber, A, Pfaltz, M. Sarcomatoid salivary duct carcinoma. Ann Diagn Pathol 2005;9:86–92CrossRefGoogle ScholarPubMed
27Khurana, KK, Pitman, MB, Powers, CN, Korourian, S, Bardales, RH, Stanley, MW. Diagnostic pitfalls of aspiration cytology of salivary duct carcinoma. Cancer 1997;81:373–83.0.CO;2-W>CrossRefGoogle ScholarPubMed
28Garcia-Bonafe, M, Catala, I, Tarragona, J, Tallada, N. Cytologic diagnosis of salivary duct carcinoma: a review of seven cases. Diagn Cytopathol 1998;19:120–33.0.CO;2-H>CrossRefGoogle ScholarPubMed
29Gilcrease, MZ, Guzman-Paz, M, Froberg, K, Pambuccian, S. Salivary duct carcinoma: is a specific diagnosis possible by fine needle aspiration cytology? Acta Cytologica 1998;42:1389–96CrossRefGoogle ScholarPubMed
30Hoang, MP, Callander, DL, Sola Gallego, JJ, Huang, Z, Sneige, N, Luna, MA et al. Molecular and biomarker analysis of salivary duct carcinomas: comparison with mammary duct carcinoma. Int J Oncol 2001;19:865–71Google ScholarPubMed
31Moriki, T, Ueta, S, Takahashi, T, Mitani, M, Ichien, M. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer 2001;93:344–50CrossRefGoogle ScholarPubMed
32Etges, A, Pinto, DS Jr, Kowalski, LP, Soares, FA, Araujo, VC. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol 2003;56:914–18CrossRefGoogle ScholarPubMed
33Vadlamudi, RK, Balasenthil, S, Sahin, AA, Keis, M, Weber, RS, Kumar, R et al. Novel oestrogen receptor coactivator PELP1/MNAR gene and ER beta expression in salivary duct adenocarcinoma: potential therapeutic targets. Hum Pathol 2005;36:670–5CrossRefGoogle ScholarPubMed
34Mukunyadzi, P, Ai, L, Portilla, D, Barnes, EL, Fan, CY. Expression of peroxisome proliferator-activated receptor gamma in salivary duct carcinoma: immunohistochemical analysis of 15 cases. Mod Pathol 2003;16:1218–23CrossRefGoogle ScholarPubMed
35Skálová, A, Stàrek, I, Vanecek, T, Kucerova, V, Plank, L, Szepe, P et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 2003;42:348–56CrossRefGoogle ScholarPubMed
36Williams, MD, Roberts, DB, Kies, MS, Mao, L, Weber, RS, El-Naggar, AK. Genetic and expression analysis of HER2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 2010;16:2266–74CrossRefGoogle ScholarPubMed
37Cornolti, G, Ungari, M, Morassi, ML, Facchetti, F, Rossi, E, Lombardi, D et al. Amplification and overexpression of HER - 2/neu gene and HER - 2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg 2007;133:1031–6CrossRefGoogle ScholarPubMed
38Williams, MD, Roberts, D, Blumenschein, GR, Teman, S, Kies, MS, Rosenthal, DI et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas. Am J Surg Pathol 2007;31:1645–52CrossRefGoogle ScholarPubMed
39Ettl, T, Schwarz, S, Kleinsasser, N, Hartmann, A, Reichert, TE, Driemel, O. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 2008;53:567–77CrossRefGoogle ScholarPubMed
40Barnes, L. Metastases to the head and neck: an overview. Head Neck Pathol 2009;3:217–24CrossRefGoogle Scholar
41Fan, CY, Wang, J, Barnes, EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridisation study. Appl Immunohistochem Mol Morphol 2008;16:54–8Google Scholar
42Kawahara, A, Harada, H, Akiba, J, Kage, M. Salivary duct carcinoma cytologically diagnosed distinctly from salivary gland carcinomas with squamous differentiation. Diagn Cytopathol 2008;36:485–93CrossRefGoogle ScholarPubMed
43Moriki, T, Ueta, S, Takahashi, T, Mitani, M, Ichien, M. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer 2001;93:344–50CrossRefGoogle ScholarPubMed
44Sartorius, C, Gille, F, Bédrossian-Pfingsten, J, Kemp, HG. Salivary duct carcinoma of the sublingual gland – a case report [in German]. Laryngorhinootologie 2006;85:517–19CrossRefGoogle ScholarPubMed
45Huh, KH, Heo, MS, Lee, SS, Choi, SC. Three new cases of salivary duct carcinoma in the palate: a radiological diagnosis and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:752–60CrossRefGoogle ScholarPubMed
46Jeong, HS, Son, YI, Ko, YH, Kim, SY. Sarcomatoid salivary duct carcinoma of the larynx. J Laryngol Otol 2006;120:154–7CrossRefGoogle ScholarPubMed
47Goel, MM, Agrawal, SP, Srivastava, AN. Salivary duct carcinoma of the larynx: report of a rare case. Ear Nose Throat J 2003;82:371–3CrossRefGoogle ScholarPubMed
48Colmenero Ruiz, C, Patron Romero, M, Martin Perez, M. Salivary duct carcinoma: a report of nine cases. J Oral Maxillofac Surg 1993;51:641–6CrossRefGoogle ScholarPubMed
49Wolff, AC, Hammond, ME, Schwartz, JN, Hagerty, KL, Allred, DC, Cote, RJ et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118–45CrossRefGoogle Scholar
50Ligibel, JA, Winer, EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol 2002;29:38–43CrossRefGoogle ScholarPubMed
51Prat, A, Paraera, M, Reyes, V, Peralta, S, Cedres, S, Andreu, J et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzmab-based therapy. Head Neck 2007;30:680–3CrossRefGoogle Scholar
52Glisson, B, Colevas, AD, Haddad, R, Krane, J, El-Naggar, A, Kies, M et al. HER 2 expression in salivary gland carcinomas: dependence on histologic subtype. Clin Cancer Res 2004;10:944–6CrossRefGoogle Scholar
53Nabili, V, Tan, JW, Bhuta, S, Sercarz, JA, Head, CS. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 2007;29:907–12CrossRefGoogle ScholarPubMed
54Nashed, M, Casasola, RJ. Biological therapy of salivary duct carcinoma. J Laryngol Otol 2008;123:250–2CrossRefGoogle ScholarPubMed
55Locati, LD, Quattrone, P, Marchiano, AV, Cantu, G, Licitra, L. A complete regression with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol 2003;14:1327–31CrossRefGoogle Scholar
56Fan, CY, Melhem, MF, Hosal, AS, Grandis, JR, Barnes, EL. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg 2001;127:1075–9CrossRefGoogle ScholarPubMed
57Locati, LD, Perrone, F, Losa, M, Mela, M, Casieri, P, Orsenigo, M et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas. Oral Oncol 2009;45:986–90CrossRefGoogle ScholarPubMed
58Hamakawa, H, Nakashiro, KI, Sumida, T, Shintani, S, Myers, JN, Takes, RP et al. Basic overview of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 2008;30:800–9CrossRefGoogle Scholar
59Milano, A, Longo, F, Basile, M, Iaffaioli, RV, Capongigro, F. Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy. Oral Oncol 2007;43:729–34CrossRefGoogle ScholarPubMed